Welcome!

News Feed Item

MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind® and future technology development opportunities were discussed and user’s validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 – 22, 2014.

The poster presentations reviewed clinical data derived from practice and clinical settings that highlighted how MelaFind has helped dermatologists in the assessment of clinically ambiguous pigmented skin lesions in various patients including young adults, an area of growing concern, and those with atypical mole syndrome. To view the posters and their accompanying abstract please click here.

The poster authored by Dr. Darrell Rigel, titled Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device for Melanoma, and outlined below was named Poster of the Day on the first day of the conference.

Highlights of the studies and the data shown in the poster presentations are as follows:

Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device (MSDSLA) for Melanoma Detection - Darrell S. Rigel, MD, MS NYU School of Medicine, New York, NY; Laura Ferris, MD, PhD, University of Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard University, Boston, MA; Clay J. Cockerell, MD, University of Texas Southwestern, Dallas, TX

  • Retrospective data from the MelaFind pivotal study was used to investigate the MelaFind multispectral images and classifier score result as a tool to differentiate cutaneous melanoma from other pigments skin lesions.
  • Results showed the average classifier scores of melanomas, high-grade lesions, non-melanoma skin cancers, and histologically benign nevi were 3.5, 2.7, 2.6 and 1.6 respectively.
  • Further results showed an increase in the mean classifier score result with each additional clinical characteristic present in the lesion.

Assessing the Predictive Probability of Melanoma and Other High Risk Pigmented Lesions Using Data Provided by a Multispectral digital Skin Lesion Analysis Device - Jane Yoo, MD, MPP, Dept. of Dermatology, Albert Einstein School of Medicine, Bronx, NY; Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell S. Rigel, MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY

  • A risk prediction model was built to assess the predictive probability of melanoma or a high-risk lesion for consideration for biopsy based on data obtained from MelaFind.
  • Results show a potential quantitative predictive capacity for presence of melanoma and other high risk pigmented lesions using the MelaFind device.

In addition to presenting data from the four studies, MELA Sciences held its third Clinical Advisory Meeting for current and prospective MelaFind users and thought leaders. In attendance was Dr. Antonanella Calame, dermatologist, dermatopathologist and medical director of Compass Dermatology and Dermatopathology in La Jolla, CA. Dr. Calame, a user of MelaFind, said, “As dermatologists, one of our most important goals is diagnosing melanoma, the deadliest form of skin cancer, at its earliest and most curable stage. The MelaFind system’s images and data analysis tools help dermatologists with one of the most challenging questions we face each day when evaluating clinically ambiguous pigments skin lesions: “Is this lesion atypical enough for me to remove and investigate further via histology?” MelaFind’s analysis of a lesion’s architectural structure gives us access to new information deeper into the skin, where the human eye cannot see, and helps us answer this critical question, improving overall outcomes for both patient and clinician. These tools are available for the first time in medicine and MelaFind is just the beginning. If patient outcomes are our foremost concern, adoption of such technologies should be widespread and soon become part of the standard of care.”

The Winter Clinical Dermatology Conference was conducted over four days and had nearly 400 participants from various fields of dermatology, medical and cosmetic. In discussing the Advances in the Diagnosis of Melanoma, Dr. Laura Ferris credited MelaFind as an important instrument in helping to detect melanoma.

Please follow us:

         

 

Twitter:

@MELASciencesIR or @MelaFind

 

StockTwits:

@MELASciencesIR

 

Facebook:

www.facebook.com/MelaFind

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as “seeks,” “look forward,” and “there seems” that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Quickly find the root cause of complex database problems slowing down your applications. Up to 88% of all application performance issues are related to the database. DPA’s unique response time analysis shows you exactly what needs fixing - in four clicks or less. Optimize performance anywhere. Database Performance Analyzer monitors on-premises, on VMware®, and in the Cloud, including Amazon® AWS and Azure™ virtual machines.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...